ReviewComputational and structural biotechnology journal2025
Pathway-guided architectures for interpretable AI in biological research.
Review in Computational and structural biotechnology journal, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
8 citing papers in PubMed.
- Flavonoids fromJournal of enzyme inhibition and medicinal chemistry · 2026Article
- Artificial intelligence-driven advancements in agricultural biotechnology.Journal, genetic engineering & biotechnology · 2026Review
- Review
- Knowledge-guided learning with curated prior genetic biomarkers for robust model interpretation.Bioinformatics (Oxford, England) · 2026Article
- Exploring the use of machine and deep learning in genome-wide association studies: a comprehensive review.BioData mining · 2026Review
- From Black Box to Biological Insight: AttentioFuse Unlocks Multi-Omics Dynamics in Lung Cancer.Cancers · 2026Article
- Serum lipidome remodeling in viral pneumonia: from pathophysiology to therapeutics.Frontiers in immunology · 2026Review
- AI-Powered Histology for Molecular Profiling in Brain Tumors: Toward Smart Diagnostics from Tissue.Cancers · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
Understanding the dysregulation of complex biological pathways is essential for uncovering molecular mechanisms and identifying novel therapeutic opportunities for complex diseases. In recent years, deep learning (DL) models have shown great potential in modeling biological multi-omics data; however, their "black box" nature limits their application in biological and clinical translation. Knowledge-guided deep learning, particularly methods based on Pathway-Guided Interpretable Deep Learning Architectures (PGI-DLA), aims to improve model performance and interpretability by integrating prior pathway knowledge into the model structure. Here, we review the current progress in PGI-DLA, focusing on omics compatibility, architectural design, feature interpretation, and biological and clinical applications. For widely used pathway databases, such as the Kyoto Encyclopedia of Genes and Genomes (KEGG), Gene Ontology (GO), Reactome, and MSigDB, we summarize their differences in knowledge scope, hierarchical structure, level of detail and curation focus. We discuss how the choice of database impacts model design, performance, and interpretability. This review provides valuable guidance for selecting and optimizing pathway databases to implement PGI-DLA to translate omics data into actionable biological and clinical insights.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.